Payton v. Abbott Labs

437 N.E.2d 171, 386 Mass. 540
CourtMassachusetts Supreme Judicial Court
DecidedJune 22, 1982
StatusPublished
Cited by393 cases

This text of 437 N.E.2d 171 (Payton v. Abbott Labs) is published on Counsel Stack Legal Research, covering Massachusetts Supreme Judicial Court primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Payton v. Abbott Labs, 437 N.E.2d 171, 386 Mass. 540 (Mass. 1982).

Opinions

Lynch, J.

This case comes before the court on certification from the United States District Court for the District of Massachusetts of four principal and several subsidiary ques[542]*542tions involving Massachusetts tort law. See S.J.C. Rule 1:03, § 1, as amended, 382 Mass. 700 (1981).

The plaintiffs in the civil action in which these questions are certified seek redress for injuries allegedly caused by the prescription drug diethylstilbestrol (DES). They brought suit in the Federal District Court in April, 1976. In July, 1979, a judge of the Federal District Court conditionally certified the plaintiff class under Fed. R. Civ. P. 23 (c)(4)(A) to permit resolution of thirteen specific class-wide issues. Payton v. Abbott Labs, 83 F.R.D. 382, 386 (D. Mass. 1979). Several of these issues are factual; the four questions here certified involve issues of Massachusetts law which the judge believed “may be determinative of various aspects of this case and as to which it appears . . . that there is no controlling precedent” in the decisions of this court.

The questions are presented by the judge in the context of a motion to dismiss, based upon the plaintiffs’ allegations. The judge summarized those allegations as follows:

“The plaintiffs are all females whose mothers ingested a drug called diethylstilbestrol . . . while pregnant with the plaintiffs. DES was marketed by the defendants as a preventative for miscarriages, and was widely prescribed by physicians. DES is transmitted to the fetus, and has been identified as one cause of a relatively rare but extremely malignant cancer called clear-cell adenocarcinoma which attacks the reproductive organs of the female children of mothers who have ingested DES. DES has also been identified as one of the causes of more common benign changes in the female children’s reproductive organs, one of which is known as adenosis. The only corrective for clear-cell ade-nocarcinoma is timely radical surgery or radiation; if treatment is not successful the disease is likely to be fatal.
“Many of the plaintiffs have no symptoms of any of these conditions. As a result of their mothers’ ingestion of DES, these plaintiffs are statistically more likely to suffer one of several abnormalities of the reproductive organ than is the general population and are to a lesser degree more likely to [543]*543contract clear-cell adenocarcinoma.
“Among the various theories of liability asserted by the plaintiffs is that the defendants were negligent in marketing DES as a miscarriage preventative without adequate testing and without appropriate warnings.
“DES was manufactured according to substantially the same formula by all of the defendants and was marketed by some defendants under its generic description. The products of the various defendants were interchangeable and were sold interchangeably by pharmacists, a fact which the defendants knew or should have known. Most of the plaintiffs are unable to identify the specific manufacturer of the DES ingested by their mothers. Pharmaceutical companies other than the named defendants also manufactured and marketed DES under its generic description, and may have supplied some of the DES ingested by the plaintiffs’ mothers. In most cases, neither the plaintiffs nor the defendants will be able to identify whose product was ingested by which mothers. Furthermore, different defendants marketed DES at different times and under different circumstances which may bear on their negligence.
“Plaintiffs have alleged two bases for recovery against all the defendants by all the plaintiffs: (1) conspiracy or joint enterprise, and (2) ‘alternative liability.’ ‘Alternative liability’ is a term used to describe a theory of recovery adopted in some jurisdictions where there is not a joint tort, that is, where the tort was committed by only one of several possible tortfeasors, but there is no way to determine which [544]*544one.[**] Different jurisdictions have developed different versions of this theory of liability with respect to the allocation of damages, the necessity of joining all possible tort-feasors as defendants, shifting the burden of proof to a defendant to establish the impossibility of that defendant’s responsibility, and right of contribution among defendants and against possible tort-feasors who are not parties. As far as the [judge] can determine, the [Supreme Judicial] Court has not addressed a claim of this kind in any form. While such a theory has never been recognized, it has never been rejected by a Massachusetts court.
“While the plaintiffs claim that DES was not efficacious in preventing miscarriages, the defendants claim that it was. If the evidence supports the defendants’ claim the trier of fact might be warranted in concluding that a particular plaintiff probably would not have been born had it not been for her mother’s ingestion of DES.
“The parties and the [judge] agree that in this diversity action the law of Massachusetts is the controlling law.”

If the plaintiffs prevail, and the defendants’ liability is established, there must be individual trials for members of the plaintiff class on the issue of damages and perhaps other issues as well.

Question One

“Does Massachusetts recognize a right of action for emotional distress and anxiety caused by the negligence of a defendant, in the absence of any evidence of physical harm, where such emotional stress and anxiety are the result of an increased statistical likelihood [that] the plaintiff will suffer serious disease in the future?” We answer, No.

[545]*545Discussion

We note initially that neither the issue of negligence nor that of causation is before us. The certified question assumes both that the defendants were negligent, and that their negligence caused the plaintiffs’ emotional distress.

No Massachusetts case has yet concluded that a plaintiff who alleges that she was a direct victim of a defendant’s negligent conduct, but who does not allege that she has suffered resulting physical harm, can recover for emotional distress. In the absence of a specific factual context, the court has declined to decide this issue.3 This court has held that a parent who was not within the zone of physical danger created by the defendant’s negligence may recover for substantial physical injuries sustained as a result of emotional distress, resulting from injuries negligently inflicted on her child. Dziokonski v. Babineau, 375 Mass. 555, 568 (1978). Here, however, the plaintiffs are assumed to be direct victims without physical injuries, since the certified question assumes that the plaintiffs were threatened with physical harm by the defendants’ negligent conduct.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Diaz v. Ramsden
67 V.I. 81 (Superior Court of The Virgin Islands, 2016)
State of New Hampshire v. Exxon Mobil Corporation & a.
168 N.H. 211 (Supreme Court of New Hampshire, 2015)
Sparrow v. Demonico
960 N.E.2d 296 (Massachusetts Supreme Judicial Court, 2012)
Schofield v. Clarke
769 F. Supp. 2d 42 (D. Massachusetts, 2011)
US Bank National Association v. Ibanez
941 N.E.2d 40 (Massachusetts Supreme Judicial Court, 2011)
McCarty v. Verizon New England, Inc.
731 F. Supp. 2d 123 (D. Massachusetts, 2010)
Papadopoulos v. Target Corporation
930 N.E.2d 142 (Massachusetts Supreme Judicial Court, 2010)
Smith v. Jenkins
718 F. Supp. 2d 155 (D. Massachusetts, 2010)
DiMare v. RealtyTrac, Inc.
714 F. Supp. 2d 199 (D. Massachusetts, 2010)
Crowl v. M. CHIN REALTY TRUST
607 F. Supp. 2d 245 (D. Massachusetts, 2009)
Ware Ex Rel. Ware v. ANW Special Educational Cooperative No. 603
180 P.3d 610 (Court of Appeals of Kansas, 2008)
Harrington v. CACV OF COLORADO, LLC
508 F. Supp. 2d 128 (D. Massachusetts, 2007)
Limone v. United States
497 F. Supp. 2d 143 (D. Massachusetts, 2007)
Godette v. Stanley
490 F. Supp. 2d 72 (D. Massachusetts, 2007)
Kelley v. Eli Lilly and Co.
517 F. Supp. 2d 99 (District of Columbia, 2007)
Kennedy v. Town of Billerica
502 F. Supp. 2d 150 (D. Massachusetts, 2007)
Yerardi v. Pacific Indemnity Co.
436 F. Supp. 2d 223 (D. Massachusetts, 2006)
Ryba v. LaLancette
417 F. Supp. 2d 199 (D. Massachusetts, 2006)

Cite This Page — Counsel Stack

Bluebook (online)
437 N.E.2d 171, 386 Mass. 540, Counsel Stack Legal Research, https://law.counselstack.com/opinion/payton-v-abbott-labs-mass-1982.